GTB 5550
Alternative Names: B7H3 TriKE™; cam1615B7H3; GTB-5550; GTB-5550 TriKE™Latest Information Update: 02 Jan 2025
At a glance
- Originator University of Minnesota
- Developer GT Biopharma
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma; Solid tumours
Most Recent Events
- 02 Jan 2025 Preclinical development for Solid tumours is ongoing the US
- 14 Nov 2024 GT Biopharma plans a phase I dose escalation basket trial trial for GBT 5550 in Solid tumours in 2025
- 28 Oct 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral, Injection)